uniQure (QURE) to Release Earnings on Thursday

uniQure (NASDAQ:QURE) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.93) per share and revenue of $4.8350 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

uniQure Stock Performance

Shares of QURE opened at $23.43 on Thursday. The stock has a market capitalization of $1.46 billion, a P/E ratio of -5.34 and a beta of 0.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The company’s fifty day moving average is $23.43 and its two-hundred day moving average is $29.29.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Market context — QURE has seen elevated volume and technical attention (50-day ~$23.43 vs. 200-day ~$29.29; 12-month low $7.76 / high $71.50), which may amplify reactions to legal headlines.
• Negative Sentiment: Multiple law firms have filed or announced class actions alleging securities fraud for purchases between Sept. 24, 2025 and Oct. 31, 2025; Rosen Law Firm is soliciting lead plaintiffs and reminding investors of upcoming deadlines. Rosen Law Notice
• Negative Sentiment: Several other prominent plaintiff firms (Berger Montague, Levi & Korsinsky, Faruqi & Faruqi, Pomerantz, Kessler Topaz, Gross Law, et al.) have issued notices or filed suits, increasing the likelihood of consolidated litigation and plaintiff competition for leadership. Gross Law Notice
• Negative Sentiment: Allegations behind the suits focus on an FDA approval delay and claims that uniQure misled investors about its pivotal study design and regulatory timing — specific allegations include that the pivotal study comparisons and BLA timeline were not fully cleared by the FDA. Such claims raise the prospect of material disclosures, remediation costs, and reputational damage. KSF Notice (FDA delay)
• Negative Sentiment: Firms are warning investors of an April 13, 2026 deadline to apply for lead-plaintiff status; consolidation and lead plaintiff selection could shape case strategy and potential settlements. Levi & Korsinsky Notice

Insiders Place Their Bets

In related news, Director Robert Gut sold 25,613 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is currently owned by insiders.

Institutional Trading of uniQure

Several large investors have recently modified their holdings of the business. Virtus Investment Advisers LLC grew its holdings in uniQure by 91.6% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 6,520 shares during the period. SummitTX Capital L.P. lifted its stake in shares of uniQure by 386.3% during the fourth quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock worth $663,000 after purchasing an additional 22,010 shares in the last quarter. Suvretta Capital Management LLC purchased a new stake in shares of uniQure in the fourth quarter worth about $29,116,000. Readystate Asset Management LP acquired a new stake in shares of uniQure in the fourth quarter valued at about $8,652,000. Finally, Orbimed Advisors LLC raised its holdings in shares of uniQure by 60.8% during the 4th quarter. Orbimed Advisors LLC now owns 737,400 shares of the biotechnology company’s stock valued at $17,646,000 after buying an additional 278,900 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Barclays assumed coverage on shares of uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price objective for the company. Wells Fargo & Company reduced their price target on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Mizuho decreased their price target on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, December 8th. The Goldman Sachs Group cut their price objective on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Finally, William Blair restated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $58.33.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.